The Market Online - At The Bell

Join our daily newsletter At The Bell to receive exclusive market insights

Medical company HeraMED has partnered with creative agency, Meerkats to progress the launch of its medical grade foetal heart monitor, HeraBEAT.

This product allows expectant mothers to monitor their baby’s heartbeat by using a simple smartphone app.

Meerkats have worked with companies such as St John Ambulance and iiNet assisting companies by offering creativity and innovation.

With the app expected to launch in May, this partnership will provide consulting services to HeraMed’s branding, digital marketing, media strategy, and social media initiatives.

HeraMED has already partnered with two leading medical organisations to diversify its product range and services.

However, it has been revealed that the first order has already been received from Dale Group International for 250 units.

Meerkats will receive a pre-determined commission from the distributor, Dale Group International for each device sold, and HeraMED believes that this will provide a considerable validation and drive market uptake for Meerkats.

HeraMED CEO David Groberman hopes this partnership will benefit both companies.

“To have secured a partnership with an agency of Meerkats caliber is a tremendous achievement for HeraMED. However, to have Meerkats add the campaign to their Meerkats Venture approach speaks volumes about their confidence in the HereBEAT device and its potential in the Australian market,” he said.

Future products from HeraMED include the EchoBeat which monitors foetal movement and Orion, an AI powered pregnancy monitor.

Please find announcement attached here

HMD by the numbers
More From The Market Online

ResMed spikes on robust results and global growth spurt

ResMed shares have climbed following the release of the company's strong Third Quarter FY2024 results.

PharmAust CEO’s sayanora triggers stock plunge

Clinical-stage biotechnology company, PharmAust shares plunged 24 per cent so this morning, following the resignation of…

Unith wraps up Q1 with $5M in cash as digital humans evolve

Unith has wrapped up Q1 of 2024 with nearly $5M in cash and opex reduced. But…

Recce wins safety board approval to dose 4g in R327 UTI infusion trial

Recce Pharma will dose patients with 4g of its R327 intravenous solution to treat UTIs in…